We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Topics
  • Rosacea
  • Cosmetic Surgery
  • Atopic Dermatitis

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • Topics
  • Rosacea
  • Cosmetic Surgery
  • Atopic Dermatitis

SUBSCRIBE: Print / Digital / eNewsletter

Study characterizes safety of pediatric psoriasis treatments

  • Cheryl Guttman Krader
Dec 7, 2017
  • Dermatology, Dermatology, Modern Medicine Feature Articles, Modern Medicine News, Treatments for Plaque Psoriasis



A retrospective review of pediatric patients treated for psoriasis with systemic agents provides much needed insight about the safety and tolerability of these medications, and its findings have already led to a change in prescribing practice.

The research, which was a joint project of the Psoriasis Investigator's Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Pediatric Psoriasis Working Group (EPPWG), also reinforced the need for prospective data collection in the pediatric psoriasis population, said Amy S. Paller, M.D., co-principal investigator of the study, and chair of dermatology at Northwestern University Feinberg School of Medicine, Chicago.

Dr. Paller told Dermatology Times, “This is the largest study evaluating children with moderate to severe psoriasis treated with systemic medications. My co-principal investigator from The Netherlands, Marieke Seyger, M.D., and I undertook this project because so little was known about the relative frequency of use of the various systemic medications for pediatric psoriasis and about their side effects in real-world practice.”

“We were also looking for regional differences because it was my impression that gastrointestinal side effects with methotrexate were much higher in Europe than in North America. The study corroborated that idea, identified differences between the two continents in folic acid regimens as the explanation, and led to a change in how folic acid is being prescribed in Europe,” she said.

The recently published retrospective study identified children with moderate to severe psoriasis treated from Dec. 1, 1990 to Sept. 16, 2014 at any of the 10 PsIG and 10 EPPWG centers for moderate to severe psoriasis using systemic medications or phototherapy for at least 3 months. After reviewing thousands of charts, only 390 children were eligible for inclusion based on having information matching the minimal core data set requirements for demographics, treatment duration, efficacy, adverse events, serious adverse events, and reason for treatment discontinuation.

“We reviewed the charts of thousands of patients to find those who met our selection criteria, and our experience clearly showed the need for standardized, prospective data collection for pediatric psoriasis,” Dr. Paller said.

“This need is unlikely to be met without industry cooperation to support creation of a single pediatric database. In the meantime, the exhaustive chart review conducted for this study made us recognize that it would be useful to develop some standard ‘templates’ for collecting data in the clinic for pediatric psoriasis patients,” she said.

THE MOST COMMONLY USED SYSTEMIC AGENT IN PEDIATRIC PSORIASIS

The study found that methotrexate was the most commonly used systemic agent in both North America (76.1%) and Europe (59.4%) followed by a biologic agent, which was used by 106 (27.2%) children, three-fourths of whom received the tumor necrosis factor inhibitor (TNF-I), etanercept (Enbrel, Amgen).

Both methotrexate and TNF-Is were associated with fewer adverse events than other systemic drugs that were used, which included acitretin, cyclosporine, and fumaric acid esters. Compared with a TNF-I, methotrexate was associated with significantly increased risks for having at least one treatment-related adverse event (1.76-fold), an adverse event leading to treatment discontinuation (5.76-fold), a treatment-related gastrointestinal (GI) adverse event (11.49-fold), and a treatment-related laboratory abnormality (3.42-fold).

The risks of having a treatment-related infection and an injection site reaction were significantly lower in patients treated with methotrexate compared with a TNF-I, although Dr. Paller provided a caveat about those findings. 

“It should be kept in mind that this was a retrospective study and the capture of information about these adverse events, and particularly infection, might have been different for the two drug groups,” she explained.

Folic acid regimen, but not total dosage of folic acid or methotrexate, predicted GI adverse events with methotrexate. Giving folic acid for 6 or 7 days per week, which was a more standard practice in North America, significantly reduced the risk compared with dosing just once a week, which was the most common regimen prescribed in Europe.  

The investigators are now analyzing data to evaluate the relative efficacy of methotrexate and TNF-I treatment for moderate to severe psoriasis in their cohort of almost 400 children.

The study was funded by a grant from the International Psoriasis Council.

 


REFERENCE

Inge M. G. J. Bronckers, MD; Marieke M. B. Seyger, MD, PhD; Dennis P. West, PhD; et al. "Safety of Systemic Agents for the Treatment of Pediatric Psoriasis," JAMA Dermatology. November 2017. DOI:10.1001/jamadermatol.2017.3029

 

Related Articles

  • Healthcare in the cloud
  • FDA moves to regulate medicines produced in bulk
  • Opposition to looming compounding practice changes
  • Clinical photography dos and don'ts
  • FDA approves a new, more powerful psoriasis drug

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Clinical Advances in Rosacea Treatment
  • Treatments for Plaque Psoriasis
  • Derm Pulse
  • Acne
Successfully Integrating Medical Weight Loss into a Cosmetic Surgery Practice
  • Twitter
  • Facebook
  • Google_plus
  • Rss
Modern Medicine Network
  • Column 1
    • Home
    • About Us
  • Column 2
    • Advertise
    • Advertiser Terms
  • Column 3
    • Privacy Statement
    • Terms & Conditions
  • Column 4
    • Editorial & Advertising Policy
    • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.